相似文献
1
Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.
World J Gastroenterol. 2008 Apr 21;14(15):2406-10. doi: 10.3748/wjg.14.2406.
2
Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
Eur J Clin Pharmacol. 2018 Jan;74(1):45-52. doi: 10.1007/s00228-017-2324-1. Epub 2017 Oct 6.
3
Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values.
BMC Gastroenterol. 2009 Jul 9;9:52. doi: 10.1186/1471-230X-9-52.
4
Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Helicobacter. 2003 Apr;8(2):111-9. doi: 10.1046/j.1523-5378.2003.00131.x.
5
Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine.
Biol Pharm Bull. 2007 May;30(5):1003-6. doi: 10.1248/bpb.30.1003.
6
Afferent signalling from the acid-challenged rat stomach is inhibited and gastric acid elimination is enhanced by lafutidine.
BMC Gastroenterol. 2009 Jun 2;9:40. doi: 10.1186/1471-230X-9-40.
7
Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist.
Aliment Pharmacol Ther. 2003 Dec;18(11-12):1149-57. doi: 10.1046/j.1365-2036.2003.01804.x.
8
Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.
World J Gastroenterol. 2008 Apr 7;14(13):2049-54. doi: 10.3748/wjg.14.2049.
9
Effect of Helicobacter pylori status on intragastric pH during administration of lafutidine or famotidine.
Hepatogastroenterology. 2007 Jun;54(76):1280-4.
10
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Aliment Pharmacol Ther. 2002 Oct;16(10):1811-7. doi: 10.1046/j.1365-2036.2002.01348.x.
引用本文的文献
1
Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial.
Gastroenterol Res Pract. 2011;2011:640685. doi: 10.1155/2011/640685. Epub 2011 May 5.
2
An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition.
World J Gastrointest Pharmacol Ther. 2010 Oct 6;1(5):112-8. doi: 10.4292/wjgpt.v1.i5.112.
3
A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.
J Gastroenterol. 2010 Dec;45(12):1219-27. doi: 10.1007/s00535-010-0283-8. Epub 2010 Jul 15.
本文引用的文献
1
Effect of Helicobacter pylori status on intragastric pH during administration of lafutidine or famotidine.
Hepatogastroenterology. 2007 Jun;54(76):1280-4.
2
[Nationwide epidemiological survey regarding heartburn and reflux esophagitis in Japanese].
Nihon Shokakibyo Gakkai Zasshi. 2005 Aug;102(8):1010-24.
3
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of rabeprazole in human plasma.
Rapid Commun Mass Spectrom. 2005;19(16):2321-4. doi: 10.1002/rcm.2066.
4
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Aliment Pharmacol Ther. 2005 Jul 1;22(1):67-74. doi: 10.1111/j.1365-2036.2005.02523.x.
5
Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials.
Clin Gastroenterol Hepatol. 2005 Jun;3(6):553-63. doi: 10.1016/s1542-3565(05)00023-6.
6
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
J Gastroenterol. 2005 May;40(5):453-8. doi: 10.1007/s00535-005-1569-0.
7
Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment.
Aliment Pharmacol Ther. 2005 Apr 1;21(7):805-12. doi: 10.1111/j.1365-2036.2005.02413.x.
8
Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists.
Aliment Pharmacol Ther. 2004 Sep 1;20(5):559-65. doi: 10.1111/j.1365-2036.2004.02147.x.
9
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Aliment Pharmacol Ther. 2003 Jun 15;17(12):1507-14. doi: 10.1046/j.1365-2036.2003.01496.x.
10
Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women.
J Gastroenterol. 2003 Mar;38 Suppl 15:3-6.
Zotero 插件